BR0212895A - Métodos e composições de novos compostos de triazina - Google Patents

Métodos e composições de novos compostos de triazina

Info

Publication number
BR0212895A
BR0212895A BR0212895-0A BR0212895A BR0212895A BR 0212895 A BR0212895 A BR 0212895A BR 0212895 A BR0212895 A BR 0212895A BR 0212895 A BR0212895 A BR 0212895A
Authority
BR
Brazil
Prior art keywords
compounds
present
compositions
methods
cell proliferation
Prior art date
Application number
BR0212895-0A
Other languages
English (en)
Inventor
Richard T Timmer
Sivaram Pillarisetti
Uday Saxena
Karen A Campbell
Christopher W Alexander
Original Assignee
Reddy Us Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Reddy Us Therapeutics Inc filed Critical Reddy Us Therapeutics Inc
Publication of BR0212895A publication Critical patent/BR0212895A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
    • C07D251/40—Nitrogen atoms
    • C07D251/42—One nitrogen atom
    • C07D251/44—One nitrogen atom with halogen atoms attached to the two other ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
    • C07D251/40—Nitrogen atoms
    • C07D251/42—One nitrogen atom
    • C07D251/46—One nitrogen atom with oxygen or sulfur atoms attached to the two other ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
    • C07D251/40—Nitrogen atoms
    • C07D251/48—Two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
    • C07D251/40—Nitrogen atoms
    • C07D251/48—Two nitrogen atoms
    • C07D251/50—Two nitrogen atoms with a halogen atom attached to the third ring carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
    • C07D251/40—Nitrogen atoms
    • C07D251/48—Two nitrogen atoms
    • C07D251/52—Two nitrogen atoms with an oxygen or sulfur atom attached to the third ring carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
    • C07D251/40—Nitrogen atoms
    • C07D251/54—Three nitrogen atoms
    • C07D251/70—Other substituted melamines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Cosmetics (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

"MéTODOS E COMPOSIçõES DE NOVOS COMPOSTOS DA TRIAZINA". A presente invenção se refere a métodos e composições compreendendo compostos que tratam condições fisiopatológicas surgidas a partir de respostas inflamatórias. Em particular, a presente invenção está direcionada a compostos que inibem ou bloqueiam a indução da sinalização associada com a resposta inflamatória produzida pelas proteínas glicatadas nas células do tecido endotelial. A presente invenção se refere a compostos que inibem a proliferação de células da musculatura lisa. Em particular, a presente invenção está direcionada a compostos que inibem a proliferação de células da musculatura lisa pela modulação de HSPGs tais como o Perlecan. A presente invenção também se refere ao uso de compostos para tratar as condições vasculares oclusivas caracterizadas pela proliferação das células da musculatura lisa tais como re-estenose e aterosclerose.
BR0212895-0A 2001-09-21 2002-09-23 Métodos e composições de novos compostos de triazina BR0212895A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32414701P 2001-09-21 2001-09-21
PCT/US2002/030177 WO2003024926A2 (en) 2001-09-21 2002-09-23 Methods and compositions of novel triazine compounds

Publications (1)

Publication Number Publication Date
BR0212895A true BR0212895A (pt) 2005-05-10

Family

ID=23262298

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0212895-0A BR0212895A (pt) 2001-09-21 2002-09-23 Métodos e composições de novos compostos de triazina

Country Status (16)

Country Link
EP (1) EP1436266A4 (pt)
JP (1) JP2005511509A (pt)
KR (1) KR20040088457A (pt)
CN (1) CN1578773A (pt)
BR (1) BR0212895A (pt)
CA (1) CA2461074A1 (pt)
EA (1) EA009728B1 (pt)
IL (1) IL160984A0 (pt)
IS (1) IS7190A (pt)
MX (1) MXPA04002680A (pt)
NO (1) NO20041187L (pt)
NZ (1) NZ532349A (pt)
PL (1) PL369600A1 (pt)
RS (1) RS34004A (pt)
WO (1) WO2003024926A2 (pt)
ZA (1) ZA200403009B (pt)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7163943B2 (en) 2001-09-21 2007-01-16 Reddy Us Therapeutics, Inc. Methods and compositions of novel triazine compounds
US7173032B2 (en) 2001-09-21 2007-02-06 Reddy Us Therapeutics, Inc. Methods and compositions of novel triazine compounds
US7132423B2 (en) 2001-09-21 2006-11-07 Reddy Us Therapeutics, Inc. Methods and compositions of novel triazine compounds
US7112587B2 (en) 2001-09-21 2006-09-26 Reddy Us Therapeutics, Inc. Methods and compositions of novel triazine compounds
US7169785B2 (en) 2001-09-21 2007-01-30 Reddy Us Therapeutics, Inc. Methods and compositions of novel triazine compounds
ATE511858T1 (de) 2002-02-05 2011-06-15 Astellas Pharma Inc 2,4,6-triamino-1,3,5-triazin-derivat
WO2004001018A2 (en) * 2002-06-25 2003-12-31 The Center For Blood Research, Inc. Vacuolins
WO2005009980A1 (en) * 2003-07-22 2005-02-03 Neurogen Corporation Substituted pyridin-2-ylamine analogues
CN1629157A (zh) * 2003-12-19 2005-06-22 中国科学院上海药物研究所 哌嗪三嗪类化合物、其制备方法及药物组合物
US7335770B2 (en) 2004-03-24 2008-02-26 Reddy U5 Therapeutics, Inc. Triazine compounds and their analogs, compositions, and methods
EP2117539B1 (en) * 2006-11-03 2010-09-01 Nerviano Medical Sciences S.r.l. A method of administering an antitumor compound
KR101314869B1 (ko) * 2010-07-29 2013-10-04 광주과학기술원 트리아진계 화합물을 유효성분으로 포함하는 당뇨병 예방 또는 치료용 약제학적 조성물
SG10201601507YA (en) * 2010-11-29 2016-04-28 Galleon Pharmaceuticals Inc Novel compounds as respiratory stimulants for treatment of breathing control disorders or diseases
US20120295911A1 (en) 2010-11-29 2012-11-22 Galleon Pharmaceuticals, Inc. Novel Compounds and Compositions for Treatment of Breathing Control Disorders or Diseases
ES2909316T3 (es) 2015-12-24 2022-05-06 Univ California Reguladores de CFTR y métodos de uso de los mismos
KR20200044873A (ko) 2017-08-24 2020-04-29 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 안구 제약학적 조성물

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2083568C1 (ru) * 1994-05-05 1997-07-10 Кубанский государственный аграрный университет Соли триазинкарбоновых кислот и средство для предпосевной обработки семян сельскохозяйственных культур
DE19531084A1 (de) * 1995-08-24 1997-02-27 Hoechst Schering Agrevo Gmbh 2,4-Diamino-1,3,5-triazine, Verfahren zu deren Herstellung und deren Verwendung als Herbizide und Pflanzenwachstumsregulatoren
CN1290264A (zh) * 1997-12-12 2001-04-04 艾博特公司 三嗪类血管生成抑制剂
EP0945447A1 (en) * 1998-03-27 1999-09-29 Janssen Pharmaceutica N.V. Trisubstituted 1,3,5-triazine derivatives for treatment of HIV infections
CA2396693A1 (en) * 1999-12-28 2001-07-05 Stephen T. Wrobleski Cytokine, especially tnf-alpha, inhibitors
WO2002036578A2 (en) * 2000-10-31 2002-05-10 Lynn Bonham Triazine derivatives as lpaat-b inhibitors and uses thereof

Also Published As

Publication number Publication date
KR20040088457A (ko) 2004-10-16
IL160984A0 (en) 2004-08-31
EA200400464A1 (ru) 2005-02-24
EP1436266A2 (en) 2004-07-14
NO20041187L (no) 2004-05-19
EA009728B1 (ru) 2008-02-28
NZ532349A (en) 2007-02-23
EP1436266A4 (en) 2004-12-22
PL369600A1 (en) 2005-05-02
JP2005511509A (ja) 2005-04-28
IS7190A (is) 2004-03-19
MXPA04002680A (es) 2004-06-18
RS34004A (sr) 2006-10-27
CA2461074A1 (en) 2003-03-27
WO2003024926A3 (en) 2003-12-11
CN1578773A (zh) 2005-02-09
WO2003024926A2 (en) 2003-03-27
ZA200403009B (en) 2007-12-27

Similar Documents

Publication Publication Date Title
BR0314670A (pt) Métodos e composições de compostos de triazina
Zhuang et al. Antioxidant and melanogenesis‐inhibitory activities of collagen peptide from jellyfish (Rhopilema esculentum)
PT991619E (pt) Inibidores da adesao celular mediada pela alfa4beta1
BR0107241A (pt) Compostos, processo de preparação dos compostos, uso dos compostos, composições fungicidas, processo de combate preventivo ou curativo dos fungos fitopatogênicos das culturas e método de tratamento preventivo ou curativo da madeira de construção
DE69633679D1 (de) Substituierte aryl-oder heteroarylamide mit retinoid-ähnlicher biologischer aktivität
BR0110587A (pt) Polìmeros dispersìveis em água pesada, sensìveis a ìon
ATE169317T1 (de) Pyridobismidazole enthaltendes rigid-rod-polymer
PT1140944E (pt) Derivados de epotilona e sua utilizacao como agentes antitumorais
BR9913842A (pt) 4-carboxiamino-2-metil-1,2,3,4-tetrahidroquinolinas como inibidores da cetp
BRPI0415773A (pt) derivados de indolinona e sua aplicação no tratamento de estados de doença tais como cáncer
DE69923671D1 (de) Verwendung von kannabidiol als entzündunghemmende mittel
BR9906438A (pt) Composição de reforço nutricional apropriada para o tratamento de úlceras de pressão
WO2003024926A3 (en) Methods and compositions of novel triazine compounds
DE69516847D1 (de) Chlorpyrimidine als zwischenprodukte
ATE220569T1 (de) Zusammensetzbares spielgerät,insbesondere zur herstellung von rollbahnen
TR200103634T2 (tr) Bitkilerde flavonoidlerin ve fenolik maddelerin miktarını arttırma yöntemi.
ATE255915T1 (de) Dermales gerüst auf der grundlage eines neutralisierten chitosan-schwammes oder eines neutralsierten gemischten chitosan-kollagen- schwammes
DE60002678D1 (de) System zur anreicherung mit eisen
PT942741E (pt) Composicoes de lectina e suas utilizacoes
ATE313562T1 (de) Antimicrobielle wirkung des ersten kationischen cluster des menschlichen lactoferrins
DK0869970T3 (da) Endothelcelleprolifereringsinhibitor og dens anvendelse
ATE516027T1 (de) Orazamid orotat zur vorbeugung von leberschäden
ATE378358T1 (de) Heparinähnliche verbindungen, ihre herstellung und verwendung zur verhinderung arterieller thrombose, verbunden mit vaskulärer verletzung und eingriffen
ATE272071T1 (de) Verwendung eines extrazellulären hämoglobins mit höherem molekulargewicht als blutersatz
FR2790767B1 (fr) Utilisation de polymeres superabsorbants pour le traitement des peaux brutes, compositions et procede correspondants et peaux ainsi traitees

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A E 7A ANUIDADES

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2060 DE 29/06/2010.